ArticleFrontiers in digital health2026
AI readiness for molecular precision medicine supply chains: evidence from Saudi Arabia.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Artificial intelligence (AI) is reshaping molecular precision medicine through biomarker discovery, genomic variant interpretation, molecular imaging, multi-omics analysis, and patient-specific therapeutic support. In Saudi Arabia, genomic medicine and digital health initiatives are expanding, yet limited evidence explains how AI readiness supports molecular diagnostics, genomic testing, biobanking, biological sample traceability, and targeted therapy delivery. Methods: A structured cross-sectional survey was completed by 350 professionals from hospitals, molecular diagnostic laboratories, genomic testing centers, biomedical laboratories, biobanks, pharmaceutical and biologic suppliers, and healthcare service providers in Saudi Arabia. Data were analyzed using partial least squares structural equation modeling. Results: AI readiness strengthened molecular data interoperability, biological sample traceability, diagnostic responsiveness, biomarker-guided decision support, and precision medicine service performance. Respondents from more AI-ready organizations reported stronger diagnostic responsiveness and fewer perceived workflow delays. Discussion: The findings connect AI readiness with molecular diagnostics, genomic services, biomarker analytics, biobanking, and healthcare supply chain coordination, providing evidence to support AI-enabled molecular medicine transformation in Saudi Arabia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.